Sometimes, you hear the bad news from a friend of a friend.
News & Analysis: Exelixis
These stocks are leading the way in their respective areas in battling cancer.
You have to look hard to see value in today's pricey market, but here are three inexpensive stocks that should be on your radar today.
Atara Biotherapeutics and Exelixis might be top takeover targets for the biotech giant.
The biotech produced solid top-line growth spurred by a new approval for Cabometyx.
EXEL earnings call for the period ending March 31, 2019.
Exelixis and Supernus Pharmaceuticals are deeply undervalued healthcare plays.
Drugmakers battle for patients.
These three cancer stocks have tremendous upside potential.
Some are really big, while others are relatively small. But all these pharmaceutical stocks look like promising picks for 2019.